Summary
No substantive prescribing-information content was provided that maps to the listed claims; therefore label alignment cannot be evaluated against the actual requested medical claims.
Category Scores
Accurate Statements
Unsupported Statements
The generic name for Levemir is insulin detemir.
The label excerpts provided do not explicitly state the relationship between brand name and generic name; without an explicit label statement, support cannot be confirmed.
Levemir is the brand name.
The label excerpts provided do not explicitly state that 'Levemir' is the brand name.
The generic drug name is insulin detemir.
The label excerpts provided do not explicitly state the generic drug name.
Insulin detemir is often written as insulin detemir injection.
The label excerpts provided do not mention the phrase 'insulin detemir injection' or discuss naming conventions.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are naming/conceptual claims and are not direct prescribing, dosing, safety, or contraindication recommendations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Evaluated
Primary Issue
The supplied label excerpts do not explicitly support the naming-related claims, and no direct medical/prescribing claim was provided for evaluation.
Suggested Improvement
Provide the exact label text (e.g., from the 'How Supplied/Description' or similar section) that states brand vs generic naming, or provide a medical/prescribing claim intended for comparison to the labeling.